Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
European Urology|June 8, 2011
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of responseDavid J Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, et al.
Cancer Immunity|December 19, 2003
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancerPadmanee Sharma, Sacha Gnjatic, Achim A Jungbluth, et al.
Clinical Genitourinary Cancer|June 15, 2015
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell TumorsDarren R Feldman, Ilya Glezerman, Sujata Patil, et al.
Cancer|September 16, 2023
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumorsSamuel A Funt, Andrea Knezevic, Kaamilah Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patientsBruce Ng, Jan Zakrzewski, Melanie Warycha, et al.
Clinical Genitourinary Cancer|April 11, 2020
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year ExperienceGopa Iyer, Christopher M Tully, Emily C Zabor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2020
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell TumorsDeaglan J McHugh, Samuel A Funt, Deborah Silber, et al.
Urologic Oncology|May 21, 2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United StatesAndrea B Apolo, Joseph W Kim, Bernard H Bochner, et al.
European Urology Oncology|May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance StatusPetros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
European Urology|June 8, 2011
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of responseDavid J Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, et al.
Cancer Immunity|December 19, 2003
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancerPadmanee Sharma, Sacha Gnjatic, Achim A Jungbluth, et al.
Clinical Genitourinary Cancer|June 15, 2015
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell TumorsDarren R Feldman, Ilya Glezerman, Sujata Patil, et al.
Cancer|September 16, 2023
Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumorsSamuel A Funt, Andrea Knezevic, Kaamilah Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patientsBruce Ng, Jan Zakrzewski, Melanie Warycha, et al.
Clinical Genitourinary Cancer|April 11, 2020
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year ExperienceGopa Iyer, Christopher M Tully, Emily C Zabor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2020
Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell TumorsDeaglan J McHugh, Samuel A Funt, Deborah Silber, et al.
Urologic Oncology|May 21, 2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United StatesAndrea B Apolo, Joseph W Kim, Bernard H Bochner, et al.
European Urology Oncology|May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance StatusPetros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Pageof 17